Clinical
Nexvet Announces Positive Top-Line Results for Proof-of-Concept Efficacy Study of NV-02 in Cats With Degenerative Joint Disease
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of…
Read more